Kurse werden geladen...
Prognose
Für dieses Unternehmen liegen uns keine Analysten-Daten vor.
Scoring-Modelle
Für dieses Unternehmen liegen uns bisher keine Scoring-Modelle vor.
Beliebteste Broker
News
- 07.12. - 13:21 Uhr
PsyBio Therapeutics successfully completes first pre-IND meeting with the FDA
PsyBio Therapeutics Corp has announced the successful completion of its initial pre-Investigational New Drug (IND) application meeting with the US Food and Drug Administration (FDA) as part of the regulatory submission process. The company said the focus of the pre-IND meeting was to discuss potential indications, manufacturing strategy, and obtain regulatory guidance as it guides its technology forward towards regulatory approval. » Mehr auf companies
- 02.12. - 14:14 Uhr
PsyBio Therapeutics presents 16 scientific abstracts highlighting its research and development efforts at two scientific conferences
PsyBio Therapeutics Corp said it presented 16 abstracts highlighting the biotechnology company's research and development initiatives at two scientific conferences. The abstracts covered topics such as biosynthetic pathway and transcriptional methodologic development; evaluation; screening and optimization of systems and organisms, and increasing bioproduction yields of natural and non-natural products. » Mehr auf companies
- 30.11. - 14:36 Uhr
PsyBio Therapeutics shares updates on intellectual property and clinical development milestones
PsyBio Therapeutics Corp., a biotechnology company developing a portfolio of psychoactive compounds aimed at the treatment of mental health disorders, told shareholders that it has filed “six additional provisional manufacturing patent applications” to expand its intellectual property portfolio. The Oxford, Ohio-based biotech said it had filed the applications with the United States Patent and Trademark Office (USPTO) and they cover a “broad range of approaches to PsyBio's biologic methodology. » Mehr auf companies
Unternehmenszahlen
(EUR) | Juni 2023 | |
---|---|---|
Umsatz | 0,00 | - |
Bruttoeinkommen | 22,90k | - |
Nettoeinkommen | 166,71k | - |
EBITDA | 143,81k | - |
Fundamentaldaten
Metrik | Wert |
---|---|
Marktkapitalisierung | 280,14k € |
Anzahl Aktien | 3,11 Mrd |
52 Wochen-Hoch/Tief | 0,0178 € - 0,0000902 € |
Dividenden | Nein |
Beta | 0,65 |
KGV (PE Ratio) | 0,01 |
KGWV (PEG Ratio) | 0,00 |
KBV (PB Ratio) | 0,01 |
KUV (PS Ratio) | 0,00 |
Unternehmensprofil
PsyBio Therapeutics Corp. ist ein Biotechnologieunternehmen, das sich auf die Erforschung, Entwicklung und Vermarktung von psychedelisch inspirierten regulierten Medikamenten zur Behandlung von psychischen und anderen Störungen in den Vereinigten Staaten konzentriert. Der Hauptsitz des Unternehmens befindet sich in Coconut Creek, Florida.
Name | PSYBIO THERAP. (SUB.VT.) |
CEO | Evan Mike Levine |
Sitz | Coconut Creek,
fl USA |
Website | |
Börsengang | 25.02.2021 |
Mitarbeiter | 4 |
Ticker Symbole
Börse | Symbol |
---|---|
Pnk | PSYBF |
München | PSYB.MU |
Assets entdecken
Shareholder von PSYBIO THERAP. (SUB.VT.) investieren auch in folgende Assets